LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 1 | H19 | 72 | hr | 1476 | 3523 | 3694 | 0.9537 | 0.9229 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 2 | H19 | 72 | hr | 1476 | 3154 | 3694 | 0.8538 | 0.7564 |
| SK-BR-3 | TGX221 | 10.0 | uM | LJP5 | 3 | H19 | 72 | hr | 1476 | 3681 | 3694 | 0.9965 | 0.9941 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 1 | O13 | 72 | hr | 1476 | 1199 | 3694 | 0.3246 | -0.1253 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 2 | O13 | 72 | hr | 1476 | 983 | 3694 | 0.2661 | -0.2227 |
| SK-BR-3 | Torin1 | 10.0 | uM | LJP6 | 3 | O13 | 72 | hr | 1476 | 1167 | 3694 | 0.3159 | -0.1397 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 1 | I19 | 72 | hr | 1476 | 1139 | 3694 | 0.3083 | -0.1523 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 2 | I19 | 72 | hr | 1476 | 1099 | 3694 | 0.2975 | -0.1704 |
| SK-BR-3 | Torin2 | 10.0 | uM | LJP5 | 3 | I19 | 72 | hr | 1476 | 1146 | 3694 | 0.3102 | -0.1492 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 1 | B13 | 72 | hr | 1476 | 1253 | 3694 | 0.3392 | -0.1009 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 2 | B13 | 72 | hr | 1476 | 1415 | 3694 | 0.3831 | -0.0278 |
| SK-BR-3 | Tozasertib | 10.0 | uM | LJP5 | 3 | B13 | 72 | hr | 1476 | 1316 | 3694 | 0.3563 | -0.0725 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 1 | P19 | 72 | hr | 1476 | 2581 | 3694 | 0.6987 | 0.4980 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 2 | P19 | 72 | hr | 1476 | 2609 | 3694 | 0.7063 | 0.5107 |
| SK-BR-3 | Trametinib | 10.0 | uM | LJP5 | 3 | P19 | 72 | hr | 1476 | 2491 | 3694 | 0.6743 | 0.4574 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 1 | M01 | 72 | hr | 1476 | 944 | 3694 | 0.2556 | -0.2403 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 2 | M01 | 72 | hr | 1476 | 1099 | 3694 | 0.2975 | -0.1704 |
| SK-BR-3 | TWS119 | 10.0 | uM | LJP5 | 3 | M01 | 72 | hr | 1476 | 1403 | 3694 | 0.3798 | -0.0332 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 1 | C13 | 72 | hr | 1476 | 3311 | 3694 | 0.8963 | 0.8273 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 2 | C13 | 72 | hr | 1476 | 3088 | 3694 | 0.8359 | 0.7267 |
| SK-BR-3 | Vemurafenib | 10.0 | uM | LJP5 | 3 | C13 | 72 | hr | 1476 | 3201 | 3694 | 0.8665 | 0.7776 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 1 | G13 | 72 | hr | 1476 | 989 | 3694 | 0.2677 | -0.2200 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 2 | G13 | 72 | hr | 1476 | 960 | 3694 | 0.2599 | -0.2330 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP5 | 3 | G13 | 72 | hr | 1476 | 872 | 3694 | 0.2361 | -0.2727 |
| SK-BR-3 | Withaferin A | 10.0 | uM | LJP6 | 1 | G13 | 72 | hr | 1476 | 893 | 3694 | 0.2417 | -0.2633 |